FIELD: medicine.
SUBSTANCE: there is provided an antibody that binds with human IL-1R and inhibits binding human IL-1 with IL-1R. The antibody is produced from hybridoma cells of line DSM ACC 2601 or it represents chimeric, humanised or with eliminated T-cell epitope version of the specified antibody or its fragment. Antibodies inhibit secretion IL-8 and IL-6 in cells of human fibroblast of line type MRC5 (ATCC CCL 171), mediated by IL-1, with 1C50 4-35 pM.
EFFECT: application of the invention provides antibody, that does not possess significant function ADCC and CDC, it can be applied for inflammatory disease treatment.
8 cl, 17 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-13 RECEPTOR ALPHA 1 ANTIBODIES AND THEIR APPLICATION | 2006 |
|
RU2413736C2 |
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| ANTIBODIES OF HIGH AFFINITY TO IL-6-RECEPTOR OF HUMANS | 2007 |
|
RU2433138C2 |
| HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN IL-4 RECEPTORS | 2009 |
|
RU2539774C2 |
| HIGH-AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | 2014 |
|
RU2663106C2 |
| IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
| RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
